First patients to test new cancer drug DXC014 in groundbreaking trial
Disease control
Not yet recruiting
This is the first-ever study in humans of a new drug called DXC014, designed for people with advanced solid tumors like lung cancer, melanoma, and prostate cancer. The main goal is to find a safe dose and understand how the body processes the drug. Researchers will also look for …
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC